Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Guardiola, Magdalena"" wg kryterium: Autor


Tytuł:
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Autorzy:
Verdaguer H; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Saurí T; Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Acosta DA; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Guardiola M; Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Sierra A; Gastrointestinal Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Hernando J; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Miquel JM; Scientific Development Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Molero C; Scientific Development Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Peiró S; Chromatin Dynamics in Cancer Group, Vall d'Hebrón Institute of Oncology (VHIO).
Serra-Camprubí Q; Chromatin Dynamics in Cancer Group, Vall d'Hebrón Institute of Oncology (VHIO).
Villacampa G; Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Aguilar S; Molecular Prescreening Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Vivancos A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Tabernero J; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; IOB-Quiron, Barcelona, Spain.; UVic-UICC, Barcelona, Spain.
Dienstmann R; Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Macarulla T; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; IOB-Quiron, Barcelona, Spain.
Pokaż więcej
Źródło:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Apr 14; Vol. 28 (8), pp. 1662-1671.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Bile Duct Neoplasms*/drug therapy
Bile Duct Neoplasms*/genetics
Cholangiocarcinoma*/drug therapy
Cholangiocarcinoma*/genetics
Cholangiocarcinoma*/pathology
Bile Ducts, Intrahepatic/pathology ; Genomics ; Humans ; Molecular Targeted Therapy ; Retrospective Studies
Czasopismo naukowe
Tytuł:
DNA Metabarcoding of Deep-Sea Sediment Communities Using COI: Community Assessment, Spatio-Temporal Patterns and Comparison with 18S rDNA.
Autorzy:
Atienza, Sara
Guardiola, Magdalena
Præbel, Kim
Antich, Adrià
Turon, Xavier
Wangensteen, Owen Simon
Pokaż więcej
Temat:
GENETIC barcoding
CYTOCHROME oxidase
SUBMARINE valleys
RECOMBINANT DNA
DNA
SEDIMENTS
Źródło:
Diversity (14242818); Apr2020, Vol. 12 Issue 4, p123-123, 1p
Czasopismo naukowe
Tytuł:
New perspectives on screening and early detection of endometrial cancer.
Autorzy:
Costas L; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Frias-Gomez J; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Guardiola M; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Benavente Y; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.
Pineda M; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Pavón MÁ; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.
Martínez JM; Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Climent M; Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Barahona M; Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Canet J; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Paytubi S; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Salinas M; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Palomero L; Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Bianchi I; ASSIR Delta, Direcció d'Atenció Primària Costa de Ponent, SAP Delta del Llobregat, Barcelona, Spain.
Reventós J; Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain.
Capellà G; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.
Diaz M; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.
Vidal A; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Piulats JM; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.; Department of Medical Oncology, IDIBELL, Catalan Institute of Cancer, Hospitalet de Llobregat, Barcelona, Spain.
Aytés Á; Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Ponce J; Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Brunet J; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.; Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain.
Bosch FX; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.
Matias-Guiu X; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Alemany L; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.
de Sanjosé S; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.; PATH, Seattle, WA.
Pokaż więcej
Corporate Authors:
Screenwide Team
Źródło:
International journal of cancer [Int J Cancer] 2019 Dec 15; Vol. 145 (12), pp. 3194-3206. Date of Electronic Publication: 2019 Jun 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Endometrial Neoplasms/*diagnosis
Biomarkers, Tumor/genetics ; Early Detection of Cancer/methods ; Endometrial Neoplasms/genetics ; Female ; Humans ; Mass Screening/methods
Czasopismo naukowe
Tytuł:
Defining a mutational signature for endometrial cancer screening and early detection.
Autorzy:
Costas L; Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain. Electronic address: .
Palomero L; Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Benavente Y; Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Spain.
Guardiola M; Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Frias-Gomez J; Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Pavón MÁ; Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Spain.
Climent M; Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Martinez JM; Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Barahona M; Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Salinas M; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Pineda M; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Bianchi I; ASSIR Delta, Direcció d'Atenció Primària Costa de Ponent, SAP Delta del Llobregat, Gerència Territorial Metropolitana Sud / ICS, Barcelona, Spain.
Reventós J; Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain.
Capellà G; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.
Diaz M; Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.
Vidal A; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Piulats JM; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Department of Medical Oncology, IDIBELL, Catalan Institute of Cancer, Hospitalet de Llobregat, Barcelona, Spain.
Ponce J; Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Brunet J; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain.
Bosch FX; Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain.
Matias-Guiu X; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Alemany L; Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Spain.
de Sanjosé S; PATH, Seattle, United States.
Aytés Á; Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain. Electronic address: .
Pokaż więcej
Corporate Authors:
Screenwide Team
Źródło:
Cancer epidemiology [Cancer Epidemiol] 2019 Aug; Vol. 61, pp. 129-132. Date of Electronic Publication: 2019 Jun 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Early Detection of Cancer/*methods
Endometrial Neoplasms/*diagnosis
Genomics/*methods
Algorithms ; Female ; Humans ; Mutation
Czasopismo naukowe
Tytuł:
DNA metabarcoding of littoral hard-bottom communities: high diversity and database gaps revealed by two molecular markers.
Autorzy:
Wangensteen OS; Department of Marine Ecology, Centre for Advanced Studies of Blanes (CEAB, CSIC), Blanes, Spain.; Norwegian College of Fishery Science, UiT the Arctic University of Norway, Tromsø, Norway.
Palacín C; Department of Evolutionary Biology, Ecology and Environmental Sciences, and Biodiversity Research Institute (IRBio), University of Barcelona, Barcelona, Spain.
Guardiola M; Department of Marine Ecology, Centre for Advanced Studies of Blanes (CEAB, CSIC), Blanes, Spain.
Turon X; Department of Marine Ecology, Centre for Advanced Studies of Blanes (CEAB, CSIC), Blanes, Spain.
Pokaż więcej
Źródło:
PeerJ [PeerJ] 2018 May 04; Vol. 6, pp. e4705. Date of Electronic Publication: 2018 May 04 (Print Publication: 2018).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Spatio-temporal monitoring of deep-sea communities using metabarcoding of sediment DNA and RNA.
Autorzy:
Guardiola M; Department of Marine Ecology, Centre for Advanced Studies of Blanes (CEAB-CSIC) , Blanes , Spain.
Wangensteen OS; Department of Animal Biology and Biodiversity Research Institute (IRBIO), University of Barcelona, Barcelona, Spain; Ecosystems & Environment Research Centre, School of Environment & Life Sciences, University of Salford, Salford, United Kingdom.
Taberlet P; Laboratoire d'Ecologie Alpine (LECA), Centre National de la Recherche Scientifique and Université Grenoble-Alpes , Grenoble , France.
Coissac E; Laboratoire d'Ecologie Alpine (LECA), Centre National de la Recherche Scientifique and Université Grenoble-Alpes , Grenoble , France.
Uriz MJ; Department of Marine Ecology, Centre for Advanced Studies of Blanes (CEAB-CSIC) , Blanes , Spain.
Turon X; Department of Marine Ecology, Centre for Advanced Studies of Blanes (CEAB-CSIC) , Blanes , Spain.
Pokaż więcej
Źródło:
PeerJ [PeerJ] 2016 Dec 21; Vol. 4, pp. e2807. Date of Electronic Publication: 2016 Dec 21 (Print Publication: 2016).
Typ publikacji:
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies